Form D · Other
Protillion Biosciences, lnc.
Burlingame, CA · CIK 0001959255
Offering snapshot reported Dec 21, 2022 · SEC filing
- Reported sold
- $19M Offering amount: $20.7M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 6, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2022 | Initial | $19,003,328 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-468247
Series A-1 Preferred Stock, Series A-2 Preferred Stock and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Dec 21, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Malek Faham | Director |
| Sean Kendall | Director |
| Curtis Layton | Director, Executive |
| David Walt | Director |
Issuer details
Industry: Other (See others in industry)
Address:
1400 Marsten Rd. Ste. M
Burlingame, CA, 94010
Burlingame, CA, 94010